Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177682 | 0.80 | ALDH1A1 (0.39) | BRD4MAOAMAOBHSD17B1ALDH1A1 | |
| SCHEMBL13526090 | 0.80 | BRD4 (0.37) | BRD4MAOAMAOBHSD17B1ALDH1A1 | |
| SCHEMBL16527196 | 0.79 | RXRA (0.39) | BRD4MAOAMAOBHSD17B1ALDH1A1 | |
| SCHEMBL3267183 | 0.77 | BRD4 (0.47) | BRD4ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL30070487 | 0.77 | MAOA (0.44) | BRD4MAOAMAOBPARP1KDM4E | |
| SCHEMBL8459403 | 0.77 | MAOA (0.44) | BRD4MAOAMAOBPARP1KDM4E | |
| SCHEMBL6158541 | 0.74 | MAOA (0.36) | BRD4P2RX7MAOAMAOBHSD17B1 | |
| SCHEMBL769176 | 0.74 | MEN1 (0.42) | BRD4MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2818508 | 0.74 | ALDH1A1 (0.41) | BRD4MAOAMAOBHSD17B1ALDH1A1 | |
| SCHEMBL30067610 | 0.74 | BRD4 (0.40) | BRD4MAOAMAOBPARP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | BRD4 1684/4885P2RX7 2329/4885MAOA 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.